To the Editor-CCR5 (R5) and CXCR4 (X4) are the major coreceptors that, along with CD4, mediate HIV entry in vivo [1, 2] . The R5 antagonists in development inhibit replication of R5-using HIV variants [3] , but they have little activity on X4 or dual/mixed populations (R5X4) [4] . Detectable R5X4 and X4 are more prevalent among the treatment experienced, which suggests that treatment may select for X4 use. This has been observed in cross-sectional analyses of clinical trials and clinical cohorts [5, 6] . In untreated patients, an increase in X4 use is associated with CD4 + T cell count decline [7] ; however, causality has been difficult to establish. The relationship between treatment and tropism has been confounded by differences in nadir CD4 + T cell counts between treated and untreated patients.
Hunt et al. [5] recently reported that patients with partial viral suppression receiving diverse combination therapies have 14-fold greater odds of harboring detectable X4-using virus than do treatmentnaive subjects, independent of CD4 + T cell counts and CCR5D32 genotype. However, the higher prevalence of X4-using viruses in treated subjects may be explained by lower pretreatment nadir CD4 + T cell counts.
AIDS Clinical Trials Group (ACTG) 175 was a randomized, placebo-controlled study conducted in 1991 to assess the benefit of combination therapy versus monotherapy in preventing clinical progression to AIDS/death in patients with CD4 + T cell counts between 200-500 cells/mm 3 [8] . A total of 2467 subjects were randomized to receive zidovudine (ZDV), didanosine (DDI), ZDV plus DDI, or ZDV plus zalcitabine. Quantitative HIV-1 RNA levels were obtained and peripheral blood mononuclear cell and MT2 cell cultures were done at selected sites. At the Stanford site, 74 subjects enrolled and had tropism determined by virus culture and MT2 cell assay at study entry; other data collected included treatment history, symptom history, age, CD4 + T cell count, HIV-1 RNA level, and CCR5D32 genotype. Fisher's exact test was used to determine associations between categorical variables, and the Wilcoxon rank-sum test was used for continuous variables. Logistic regression was used to perform a multivariate analysis. All analyses were performed with SAS (version 9.1; SAS Institute).
Of the 74 subjects, 45 were treatment naive and 29 had received prior ZDV (median, 563 days; range, 15-1492 days). Sixteen had detectable syncytia (SI) on MT2 cell culture, whereas 58 had no detectable SI (NSI) on MT2 cell culture. Subjects with SI virus were more likely to have received prior treatment with ZDV (10/ ), Age, P p .044 baseline CD4 + T cell count, baseline viral load, present or prior HIV-related symptoms, and proportion of CCR5D32 heterozygotes were not different between the 2 groups (table 1) . ZDV exposure remained significantly associated with SI virus at baseline in a multivariate logistic regression model that controlled for the above variables, with an odds ratio of 8.01 (95% confidence interval, 1.62-39.7). Baseline CD4 + T cell count showed a trend toward association with tropism in the univariate analysis and was significant in the multivariate model, with an odds ratio of 1.01 (95% confidence interval, 1.00-1.01).
Our data are in agreement with those of Hunt et al. in that they indicate that treatment may enhance selection of X4-using virus, even with ZDV monotherapy. The frequencies of SI virus in the treatment-experienced group (34%) and the treatment-naive group (11%) were similar to those reported by Hunt, despite the different assays used to measure tropism. Although we did not have nadir CD4 + T cell count data in this cohort with prior ZDV monotherapy only, the subjects were likely at their nadir at the time of enrollment. Evidence for this is provided by the overall results of ACTG 175-subjects who were treatment naive and received ZDV monotherapy achieved a maximum CD4 + T cell count gain of 14 cells/mm 3 at week 8 and had returned to baseline CD4 + T cell counts by week 20 [8] . Prior studies have shown that ZDV is preferentially phosphorylated in activated T cells that express high levels of R5 and has less activity in resting T cells [9] . An earlier study comparing ZDV monotherapy with DDI monotherapy showed that ZDV had better activity against NSI (R5-using only) than against SI (X4-using) biological clones, whereas DDI had better activity against SI clones [10] . This ZDV-specific effect could have contributed to our results, although specific treatments did not appear to have differential effects in Hunt et al.'s study. The other possibility, as Hunt et al. pointed out, is that treatment-mediated reductions in R5 expression and associated reduced immune activation may favor the selection of X4-using viruses [11] . Whatever the mechanism, antiretroviral therapy appears to select for an increase in X4-using viruses among patients who have persistent viremia. In defining the strategic use of R5 inhibitors, it may be important to focus on drug-naive patients, who are less likely to have developed X4-using viruses.
